Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study

Abstract

Background

Countries have different diagnostic procedures and treatment regimens for inflammatory bowel disease (IBD) patients. In addition to differences in population characteristics, completeness of data and health registries, different follow-up time and case definitions can have a large impact on estimates of the incidence and prevalence of IBD.

Aim

The aim of this study was to use hospital and prescription data to estimate incidence and prevalence of Crohn’s disease (CD) and ulcerative colitis (UC), using different case definitions.

Methods

This study used nationwide data from the Norwegian Patient Registry (2008 to 2017) and the Norwegian Prescription Database (2004 to April 2018). Incidence and prevalence were estimated using different case definitions of an IBD patient, varying the number of IBD-related hospital visits and IBD prescriptions required. The base case definition included patients with at least one IBD hospital visit and two IBD prescriptions or two IBD hospital visits.

Results

From 2010 to 2017, 16,758 incident IBD patients fulfilled our base case definition, with 6045 diagnosed with CD (36.1%) and 10,713 (63.9%) with UC. For CD, 47.2% of the patients were male while 53.8% of UC patients were male. The base case incidence varied between 14.1 and 16.0 per 100,000 person-years for CD and 24.7 and 28.4/100,000 person-years for UC patients in the years 2010–2017. When we required at least two IBD hospital visits, not utilizing the prescription data, the CD incidence was 22.3 per 100,000 person-years in 2010 and 13.9 per 100,000 person-years in 2017. For UC, the incidence was 47.4 and 20.6 per 100,000 person-years in 2010 and 2017. In 2017, the prevalence of CD was 0.27% (95% CI: 0.26–0.27) and 0.50% (95% CI: 0.490–0.502) for UC.

Conclusion

According to our base case definition, the incidence of IBD in Norway was stable from 2010 to 2017. Both the incidence and prevalence of IBD in Norway is among the highest in the world. Moreover, the study also highlights the consequences of different case definitions.

Keywords:

• inflammatory bowel disease
• incidence
• prevalence
• real-world data

Disclosure

SSL reports research funding from Takeda during the conduct of the study and personal fees from Takeda outside the submitted work. HOM reports research funding from Takeda during the conduct of the study and personal fees from Takeda outside the submitted work. MLH reports unrestricted research grants from Tillotts, Ferring and Takeda; advisory board for Takeda; and speaker fees from AbbVie, Meda and Takeda. BM serves in the advisory board for AbbVie, Jansen, Hospira, Orion Pharma, Pfizer, Sandoz, Vifor Pharma; reports speaker fees from Takeda, Pfizer, Orion Pharma, Hospira, Ferring, and Cosmo Pharma. KA reports personal fees from Takeda. The authors report no other conflicts of interest in this work.

Additional information

Funding

This work was financially supported by Takeda.